A Phase 1 Dose Escalation Study of IPI-493

This study has been terminated.
(Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus exclusively on retaspimycin)
Sponsor:
Information provided by:
Infinity Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00724425
First received: July 25, 2008
Last updated: June 10, 2011
Last verified: June 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: July 2011
  Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)